Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

Lenalidomide enhances anti-myeloma cellular immunity

(2012) Katarina Luptakova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses

(2012) Kimberly Noonan et al.   CLINICAL CANCER RESEARCH

Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study

(2012) Christine Wolschke et al.   EXPERIMENTAL HEMATOLOGY

Current treatment strategies with lenalidomide in multiple myeloma and future perspectives

(2012) Alessandra Larocca et al.   Future Oncology

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

(2012) K. Sockel et al.   HAEMATOLOGICA

Expansion of Polyfunctional HIV-Specific T Cells upon Stimulation with mRNA Electroporated Dendritic Cells in the Presence of Immunomodulatory Drugs

(2012) B. De Keersmaecker et al.   JOURNAL OF VIROLOGY

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

(2011) E. Kneppers et al.   BLOOD

Myeloid-derived suppressor cells - their role in haemato-oncological malignancies and other cancers and possible implications for therapy

(2011) Tamar Tadmor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma

(2011) B. Neuber et al.   JOURNAL OF IMMUNOLOGY

Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation

(2011) J M McDaniel et al.   LEUKEMIA

Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign

(2010) Isabel Poschke et al.   CANCER RESEARCH

Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide

(2010) Mei-Chuan Huang et al.   CLINICAL IMMUNOLOGY

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

(2010) A. K. Gandhi et al.   CURRENT CANCER DRUG TARGETS

Myeloid-derived suppressor cell heterogeneity and subset definition

(2010) Elisa Peranzoni et al.   CURRENT OPINION IN IMMUNOLOGY

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

(2010) M. K. Brimnes et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

(2009) M Lioznov et al.   BONE MARROW TRANSPLANTATION

CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

(2009) Sylvia Feyler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

(2009) Marie von Lilienfeld-Toal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor

(2009) Bastian Hoechst et al.   HEPATOLOGY

IL4Rα + Myeloid-Derived Suppressor Cell Expansion in Cancer Patients

(2009) Susanna Mandruzzato et al.   JOURNAL OF IMMUNOLOGY

Immunosuppressive CD14+HLA-DRlow/−monocytes in prostate cancer

(2009) Stanimir Vuk-Pavlović et al.   PROSTATE

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phenotype and function of human T lymphocyte subsets: Consensus and issues

(2008) Victor Appay et al.   CYTOMETRY PART A

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

(2008) Bastian Hoechst et al.   GASTROENTEROLOGY

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells

(2008) M C Minnema et al.   LEUKEMIA

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

(2008) M. Jinushi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA